1
|
Dreisbach AW, Lertora JJL. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4:1065-74. [PMID: 18680441 PMCID: PMC2745294 DOI: 10.1517/17425255.4.8.1065] [Citation(s) in RCA: 165] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
BACKGROUND Chronic renal failure (CRF) has been shown to significantly reduce the nonrenal clearance and alter bioavailability of drugs predominantly metabolized by the liver and intestine. OBJECTIVES The purpose of this article is to review all significant animal and clinical studies dealing with the effect of CRF on drug metabolism and transport. METHODS A search of the National Library of Medicine PubMed was done with terms such as chronic renal failure, cytochrome P450 [CYP], liver metabolism, efflux drug transport and uptake transport, including relevant articles back to 1969. RESULTS Animal studies in CRF have shown a significant downregulation (40-85%) of hepatic and intestinal CYP metabolism. High levels of parathyroid hormone, cytokines and uremic toxins have been shown to reduce CYP activity. Phase II reactions and drug transporters such as P-glycoprotein and organic anion transporting polypeptide are also affected. CONCLUSION CRF alters intestinal, renal and hepatic drug metabolism and transport producing a clinically significant impact on drug disposition and increasing the risk for adverse drug reactions.
Collapse
Affiliation(s)
- Albert W Dreisbach
- University of Mississippi Medical Center, Division of Nephrology, Department of Medicine, 2500 North State Street, Jackson, MS 39216, USA.
| | | |
Collapse
|
2
|
Dreisbach AW, Lertora JJL. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003; 16:45-50. [PMID: 12535300 DOI: 10.1046/j.1525-139x.2003.03011.x] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
There is abundant evidence that chronic renal failure (CRF) and end-stage renal disease (ESRD) alter drug disposition by affecting protein and tissue binding and reducing systemic clearance of renally cleared drugs. What is not fully appreciated is that CRF can significantly reduce nonrenal clearance and alter the bioavailability of drugs predominantly metabolized by the liver. Animal studies in CRF have shown a major down-regulation (40-85%) of hepatic cytochrome P-450 metabolism involving specific isozymes. Phase II reactions such as acetylation and glucuronidation are also involved, with some isozymes showing induction and others inhibition. Hepatic enzymes exhibiting genetic polymorphisms such as N-acetyl-transferase-2 (NAT-2), which is responsible for the rapid and slow acetylator phenotypes, have been shown to be inhibited by ESRD and reversed by transplantation. There is some evidence pointing to the possibility of inhibitory factors circulating in the serum in ESRD patients which may be dialyzable. This review includes all significant animal and clinical studies using the search terms "chronic renal failure,""cytochrome P-450," and "liver metabolism" over the past 10 years obtained from the National Library of Medicine MEDLINE database, including relevant articles back to 1969.
Collapse
Affiliation(s)
- Albert W Dreisbach
- Division of Nephrology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
| | | |
Collapse
|
3
|
Zini R, Riant P, Barré J, Tillement JP. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). Clin Pharmacokinet 1990; 19:218-29. [PMID: 2203581 DOI: 10.2165/00003088-199019030-00005] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Part I of this article, which appeared in the previous issue of the Journal, discussed the implications of variations in plasma protein levels in a number of diseases: hepatic and renal disease, acute myocardial infarction, burns, cancer, diabetes mellitus, hyperlipidaemia and inflammatory diseases. In Part II the authors continue their review with a further range of disease states, and consider their import for drug dosages.
Collapse
Affiliation(s)
- R Zini
- Department Hospital-Universitaire de Pharmacologie, Créteil, France
| | | | | | | |
Collapse
|
4
|
|
5
|
Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1987; 12:402-32. [PMID: 3301150 DOI: 10.2165/00003088-198712060-00002] [Citation(s) in RCA: 158] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The ability of a wide variety of anionic, cationic, and neutral drugs to bind in a reversible manner to plasma proteins has long been recognised. Non-steroidal anti-inflammatory drugs (NSAIDs) are distinguished as a class by the high degree to which they bind to plasma protein. Plasma protein binding properties are primary determinants of the pharmacokinetic properties of the NSAIDs. Theoretical relationships are reviewed in order to define quantitatively the impact of plasma protein binding on clearance, half-life, apparent volume of distribution, and the duration and intensity of pharmacological effect. The quantitative relationships governing competitive displacement binding interactions are also presented. Experimental methods for in vitro and in vivo determination of the degree of plasma protein binding are discussed. The more common in vitro methods are equilibrium dialysis and ultrafiltration. Methods for characterising the degree of plasma protein binding in vivo consist of either measuring the concentration of drug at equilibrium in an implanted semipermeable vessel or measuring the relative drug concentrations in two body spaces with different protein content. Emphasis is given to the comparative advantages and disadvantages of experimental application of the various in vitro and in vivo methods. Plasma protein binding is discussed as a determinant of the trans-synovial transport of NSAIDs. Trans-synovial transport of NSAIDs appears to be a diffusional process. Limited data in humans receiving ibuprofen, indomethacin, aspirin, carprofen, alclofenac, or diclofenac suggest that clearance of each of these NSAIDs from the synovium is slower than clearance from plasma. The clinical data relevant to the relationship between plasma NSAID concentration and various measures of anti-inflammatory effect are reviewed. A positive correlation between plasma NSAID concentration and anti-inflammatory effect has been observed in only one study on naproxen and one study on piroxicam. In several other studies, the lack of concentration-response correlations is generally attributed to the relatively subjective, quantitatively inexact methods used to assess anti-inflammatory effect and analgesia in arthritic patients, as well as the substantial interpatient variabilities in the fraction of unbound NSAID and the unbound plasma NSAID concentration. In view of the generally poor correlation between concentration and therapeutic response, routine therapeutic monitoring of total plasma NSAID concentration is not recommended as a means of titrating individual dosages to the desired effect in each patient.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
6
|
Abstract
The salicylates are the most commonly used analgesic, antipyretic, and anti-inflammatory drugs. They are available in hundreds of preparations, many of which are over-the-counter medications. The easy access to large quantities of the drug and the widespread perception that the drug is harmless have contributed to salicylate intoxication becoming a serious and common problem, particularly among the pediatric and geriatric populations. Salicylate is still the major drug for the treatment of rheumatic diseases. The use of salicylate in high doses for the management of these patients requires close monitoring of serum salicylate levels because of the large interindividual variation in dose-serum level relationships and the narrowness of the therapeutic range. Thus, both for the management of patients intoxicated with salicylate and patients who are on high-dose salicylate therapy, the measurement of serum salicylate levels is an important clinical laboratory service. Recent research on the inhibitory effect of aspirin on platelet aggregation has led to the prophylactic use of aspirin in low doses as an antithrombotic drug. This new therapeutic use of aspirin can be aided by monitoring low serum levels of salicylate and perhaps aspirin itself. This article reviews the current state of the knowledge of the pharmacokinetics and clinical toxicology of salicylate, the clinical usefulness of salicylate measurement by the clinical laboratory, and recent development in the analytical technology for salicylate analysis.
Collapse
|
7
|
Abstract
The use of salicylates in rheumatic diseases has been established for over 100 years. The more recent recognition of their modification of platelet and endothelial cell function has lead to their use in other areas of medicine. Aspirin (acetylsalicylic acid) is still the most commonly used salicylate. After oral administration as an aqueous solution aspirin is rapidly absorbed at the low pH of the stomach millieu. Less rapid absorption is observed with other formulations due to the rate limiting step of tablet disintegration - this latter factor being maximal in alkaline pH. The rate of aspirin absorption is dependent not only on the formulation but also on the rate of gastric emptying. Aspirin absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes. Hydrolysis of aspirin to salicylic acid by nonspecific esterases occurs in the liver and, to a lesser extent, the stomach so that only 68% of the dose reaches the systemic circulation as aspirin. Both aspirin and salicylic acid are bound to serum albumin (aspirin being capable of irreversibly acetylating many proteins), and both are distributed in the synovial cavity, central nervous system, and saliva. The serum half-life of aspirin is approximately 20 minutes. The fall in aspirin concentration is associated with a rapid rise in salicylic acid concentration. Salicylic acid is renally excreted in part unchanged and the rate of elimination is influenced by urinary pH, the presence of organic acids, and the urinary flow rate. Metabolism of salicylic acid occurs through glucuronide formation (to produce salicyluric acid), and salicyl phenolic glucoronide), conjugation with glycine (to produce salicyluric acid), and oxidation to gentisic acid. The rate of formation of salicyl phenolic glucuronide and salicyluric acid are easily saturated at low salicylic acid concentrations and their formation is described by Michaelis-Menten kinetics. The other metabolic products follow first-order kinetics. The serum half-life of salicylic acid is dose-dependent; thus, the larger the dose employed, the longer it will take to reach steady-state. There is also evidence that enzyme induction of salicyluric acid formation occurs. No significant differences exist between the pharmacokinetics of the salicylates in the elderly or in children when compared with young adults. Apart from differences in free versus albumin-bound salicylate in various disease states and physiological conditions associated with low serum albumin, pharmacokinetic parameters in patients with rheumatoid arthritis, osteoarthritis, chronic renal failure or liver disease are essentially the same.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
8
|
Graham GG, Day RO, Champion GD, Lee E, Newton K. Aspects of the Clinical Pharmacology of Non-steroidal Anti-inflammatory Drugs. ACTA ACUST UNITED AC 1984. [DOI: 10.1016/s0307-742x(21)00500-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Abstract
The protein binding of acidic drugs but not basic drugs is decreased in serum from patients with poor renal function. This decreased binding is due to the retention of compounds that displace drugs from their binding sites on albumin. Phenytoin and valproic acid are the 2 drugs that require a change in the values for therapeutic levels to allow for this decreased binding.
Collapse
|
10
|
Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3:155-93. [PMID: 6356890 DOI: 10.1016/s0272-6386(83)80060-2] [Citation(s) in RCA: 163] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The data base for rational guidelines to safe, efficacious drug prescribing in adults with renal insufficiency are presented in tabular form. Current medical literature was extensively surveyed to provide as much specific information as possible. When information is lacking, however, recommendations are based on pharmacokinetic variables in normal subjects. Nephrotoxicity, important adverse effects, and special considerations in renal patients are noted. Adjustments are suggested for hemodialysis and peritoneal dialysis when appropriate.
Collapse
|
11
|
Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1983; 8:297-331. [PMID: 6352138 DOI: 10.2165/00003088-198308040-00003] [Citation(s) in RCA: 182] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The number of non-steroidal anti-inflammatory drugs (NSAIDs) available for clinical use has dramatically increased during the last decade. As a general rule, NSAIDs are well absorbed from the gastrointestinal tract, with the exception of aspirin (and possibly diclofenac, tolfenamic acid and fenbufen) which undergoes presystemic hydrolysis to form salicylic acid. Concomitant administration of NSAIDs with food or antacids may in some cases lead to delayed or even reduced absorption. The NSAIDs are highly bound to plasma proteins (mainly albumin), which limits their body distribution to the extracellular spaces. Apparent volumes of distribution of NSAIDs are, therefore, very low and usually less than 0.2 L/kg. The elimination of these drugs depends largely on hepatic biotransformation; renal excretion of unchanged drugs is usually small (less than 5% of the dose). Total body clearance is low and for most NSAIDs is less than 200 ml/min. The effect of age and disease on the disposition of NSAIDs has not been extensively studied. Due to the central role of the liver in the overall elimination of the majority of these compounds, hepatic disease will most likely lead to a significant alteration in their pharmacokinetic behaviour. NSAIDs have been reported to be involved in numerous pharmacokinetic drug interactions. Aspirin decreases the plasma concentrations of many other NSAIDs, although the clinical significance of this is uncertain. Due to the extremely high plasma protein binding of NSAIDs (around 99% in many cases), competition for the same binding sites on plasma proteins may be at least partly responsible for some interactions of NSAIDs with other highly bound drugs; however, another mechanism such as decreased metabolism or decreased urinary elimination is usually involved as well. The most important interactions with NSAIDs are those involving the oral anticoagulants and oral hypoglycaemic agents, though not all NSAIDs have been found to interact with these drugs. In clinical practice, there appear to be no clear-cut guidelines to assist the clinician in the selection of the most appropriate drug for an individual patient. The selection of an anti-inflammatory drug should be based on clinical experience, patient convenience (e.g. once or twice daily dosage schedule), side effects and cost. Since a marked interindividual variability exists in the clinical response to a given NSAID, clinicians prescribing these agents may try several of them sequentially until an adequate response is obtained.
Collapse
|
12
|
|
13
|
Verbeeck RK, Branch RA, Wilkinson GR. Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet 1981; 6:329-45. [PMID: 7037261 DOI: 10.2165/00003088-198106050-00001] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
14
|
Abstract
Pharmacokinetics of drugs taken in overdose may differ from those observed following therapeutic doses. Differences are due both to dose-dependent changes and to effects of drugs or pathophysiological consequences of the overdose on kinetics. Dose-dependent changes in rate and extent of absorption, bioavailability (saturation of first-pass metabolism), distribution (saturation of protein binding sites) and metabolism are discussed. Gastrointestinal motility is affected both by specific drug actions, such as delayed gastric emptying by anticholinergic drugs, and by general nervous system depression caused by many drugs. Drug-induced circulatory insufficiency may retard tissue distribution and reduce clearance. Disturbances in blood and urine pH may alter distribution and clearance of weak acids and bases. Drug-induced renal or hepatic failure can significantly decrease clearance. Hypothermia is a common complication of drug overdose and might retard distribution and also reduce clearance. The data concerning pharmacokinetics during overdose are usually incomplete and difficult to interpret. Doses and times of ingestion are uncertain, duration of blood and urine sampling is often inadequate to distinguish absorption from distribution and elimination phases, active metabolites are not measured, protein binding is not determined and clinical features of patients not adequately described. We have, however, reviewed available data for salicylate, paracetamol (acetaminophen), barbiturates, ethchlorvynol, glutethimide, chloral hydrate, tricyclic antidepressants, lithium, phenytoin, ethanol, theophylline, digoxin, amphetamine and phencyclidine.
Collapse
|
15
|
Abstract
The following methods for producing renal dysfunction in rats were compared: single-step 5/6th nephrectomy, two-step 5/6th nephrectomy, bilateral ureteral ligation, and uranyl nitrate injection. Control groups consisted of single- and two-step sham-operated animals and animals that received an injection of normal saline solution. The methods were evaluated on the basis of the following criteria, which were assessed daily for 6 days: survival, body weight, hematocrit, serum creatinine concentration, serum urea nitrogen concentration, serum glutamic pyruvic transaminase activity, serum albumin concentration, and serum protein binding of salicylate (determined every other day). Animals with bilateral ureteral ligation survived only 2 days, single-step 5/6th nephrectomy caused a high incidence of fatalities. Some of the methods were associated with the development of hypoalbuminemia, but no significant elevation of transaminase activity occurred. Serum protein binding of salicylate was reduced in rats with renal dysfunction. A strong positive correlation between the creatinine and urea nitrogen concentrations in the serum of animals with renal dysfunction (r = 0.91, p less than 0.001) and a negative correlation between the serum albumin concentration and salicylate free fraction (r = -0.71, p less than 0.001) were found. Uranyl nitrate injection has the advantages of technical simplicity, a high survival rate (no deaths in this study), and relatively consistent and sustained diminution of renal function (as reflected by serum creatinine and urea nitrogen concentrations).
Collapse
|
16
|
Abstract
In a 67-year-old man who had a feeding jejunostomy because of dysphagia paralytica, the absorption of aspirin was measured in terms of serum salicylate concentration. A 975-mg dose of aspirin was given as a slurry in water directly into the feeding tube. Peak serum levels of salicylate were well correlated with those in previous studies of aspirin absorption by the oral route in a geriatric population. However, unexpectedly, the half-life of the drug in this patient was twice as long (7.5 hours) as that found in six previous studies (3.7 hours) of elderly patients given similar doses.
Collapse
|
17
|
Pachman LM, Olufs R, Procknal JA, Levy G. Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. ARTHRITIS AND RHEUMATISM 1979; 22:826-31. [PMID: 465097 DOI: 10.1002/art.1780220804] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Free and total (sum of free and protein bound) salicylate concentrations in serum were determined in 17 children (age: 4-17 years) with definite juvenile rheumatoid arthritis. These measurements were carried out immediately before and 2, 4, and 8 hours after the morning dose during a strict 8 hourly aspirin treatment regimen (regular tablets) started 5 days earlier. The ratio of the 0 to 8 hour total salicylate concentrations was 0.95 +/- 0.10 (mean +/- SD), indicating that steady state had been attained. The ratio of the maximum to minimum concentrations during the dosing interval ranged from 1.05 to 2.26 and decreased with increasing average concentration. The concentration ratio was less than 1.3 at average salicylate concentrations above 20 mg/100 ml. It is concluded that the timing of a blood sample is not critical for monitoring steady state serum salicylate concentrations in the usual therapeutic range if the dosing interval is 8 hours or less. Free salicylate concentrations increased more than proportionately with increasing total concentrations due to the concentration dependent protein binding of the drug in serum.
Collapse
|
18
|
Abstract
Drug prescribing for patients with renal failure should incorporate adjustment of dosage regimens in order to avoid accumulation and thus adverse effects. Drugs usually eliminated by the kidneys require the most modification. Since immediate therapeutic efficacy is of importance, the initial or loading dose is essentially unaltered for patients with renal dysfunction. Maintenance doses can be adjusted by either lengthening the interval between doses of by reducing the size of individual doses. In clinical practice, a combination of both methods is used. Serum levels should be used as guides whenever possible. In interpreting these levels, recognition of decreased plasma protein binding and prolonged elimination half-lives in renal failure is imperative. In patients requiring dialysis, consideration must be given to adjustments for drug removal by the artificial membrane. Small molecules unbound to proteins are most easily removed. Specific guidelines for therapy with common drugs prescribed for patients with renal failure are given. These include: (1) narcotics and analgesics; (2) psychotherapeutic drugs; (3) cardiovascular drugs; and (4) antimicrobial agents.
Collapse
|
19
|
|
20
|
Champion GD, Graham GG. Pharmacokinetics of non-steroidal anti-inflammatory agents. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1978; 8 Suppl 1:94-100. [PMID: 365162 DOI: 10.1111/j.1445-5994.1978.tb04794.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
21
|
Abstract
The factors affecting solute movement across the membrane during haemodialysis are well understood. Likewise the mathematics of drug kinetics are well described. However, studies of the effects of artificial kidneys on drug kinetics have often been limited by a lack of attention to proper methods of calculating solute clearance by the artificial kidney.
Collapse
|
22
|
Abstract
Studies of the rates of elimination of drugs normally biotransformed in man have been carried out in uremic patients. Drug oxidations are normal or accelerated. Reduction is slowed. Glucuronide and glycine conjugations are normal whereas acetylation may be normal or slowed. Many hydrolyses are slowed. Thus, the usual dosages of metabolized drugs may have to be altered to properly individualize therapy for patients with renal failure.
Collapse
|
23
|
Pérez-Mateo M, Erill S. Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency. Eur J Clin Pharmacol 1977; 11:225-31. [PMID: 856605 DOI: 10.1007/bf00606415] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The plasma protein binding of a representative acidic drug, salicylate, and a representative basic drug, quinidine, has been studied in patients with several diseases that are sometimes associated with uraemia or a change in serum albumin level. Decreased plasma protein binding of salicylate was observed in plasma from patients with uraemia and liver disease. Low albumin levels in these patients could only account inpart for the decreased binding. On the other hand, salicylate binding to plasma proteins appeared to be increased in patients with hypoxia. Decreased plasma protein binding of quinidine was observed in some patients with uraemia and in the majority of patients with liver disease.
Collapse
|
24
|
Odar-Cederlof I. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation. Clin Pharmacokinet 1977; 2:147-53. [PMID: 324689 DOI: 10.2165/00003088-197702020-00005] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The plasma protein binding of phenytoin and warfarin was studied in vitro by equilibrium dialysis at 37 degrees C in plasma from patients with chronic renal disease before and after renal transplantation. The plasma protein binding of these two drugs (which is decreased in the uraemic state), increased dramatically during the first 2 to 4 postoperative days and reached values slightly below normal on the 10th to the 15th postoperative day. This increase in binding is suggested to be due to the elimination of inhibiotrs of drug albumin binding, earlier shown to be present in uraemic serum.
Collapse
|
25
|
Berg KJ. Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency. Eur J Clin Pharmacol 1977; 11:111-6. [PMID: 837963 DOI: 10.1007/bf00562901] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The effect of acetylsalicylic acid (ASA) in patients with renal insufficiency has been examined. In one investigation (A), in patients with a mean GFR of 23.0 ml/min the acute effects of ASA 750 mg i.v. (lysine-ASA 7.5 ml) and 0.9% NaCl 7.5 ml on renal water and solute output and on the clearance of inulin, creatinine and PAH were compared. In another (B) the effects of simultaneous administration of ASA 750 mg or 0.9% NaCl 7.5 ml i.v. with an infusion of furosemide 250 mg were investigated in six patients (mean GFR 12.9 ml/min) in a cross-over study. In study A there was a significant fall in urinary sodium excretion within the first 15 min after ASA administration, with a maximal decrease to 21% of the control period. Urine flow fell to 35%, osmolal clearance to 41%, inulin clearance to 54% and PAH clearance reabsorption of sodium increased. The effect of ASA lasted for 2-6 h. The mean salicylic acid concentration during the first two hours after ASA administration was 60.0 mug/ml, and the mean protein bound salicylic acid (SA) was 70.4%. There was no effect of placebo (0.9% NaCl 7.5 ml) on renal function. Pretreatment with ALA 750 mg i.v. attenuated the diuretic effect of furosemide 250 mg, and reduced creatinine clearance significantly within 0-2 h after drug administration.
Collapse
|
26
|
Abstract
Plasma from patients with renal failure has decreased binding of many drugs. The decreased binding of anionic drugs is pronounced and is apparently due to occupation of protein binding sites by non-dialysable endogenous acidic compounds. Organic bases seem to bind normally, particularly if hypoproteinaemia or hypoalbuminaemia are not present. This modification of drug binding to plasma proteind from uraemic patients must be considered when plasma concentrations of acidic drugs are measured.
Collapse
|
27
|
Odar-Cederlöf I, Borgå O. Lack of relationship between serum free fatty acids and impaired plasma protein binding of diphenylhydantoin in chronic renal failure. Eur J Clin Pharmacol 1976; 10:403-5. [PMID: 1001355 DOI: 10.1007/bf00563076] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The plasma protein binding of diphenyldantoin (DPH) in 13 patients with varying degrees of renal failure was considerably less than in normal healthy subjects confirming early studies. The fraction of unbound DPH was correlated with serum creatinine (r = 0.81, p less than 0.001), but there was no significant correlation with the serum concentration of free fatty acids, triglycerides or cholesterol.
Collapse
|